Genetic regulation of β-ureidopropionase and its possible implication in altered uracil catabolism
Authors:
- Hany H. EzzeldinHEHany H. Ezzeldin
- Vincenzo GuarcelloVGVincenzo Guarcello
- Lori K. MattisonLMLori K. Mattison
- Brooke L. FridleyBFBrooke L. Fridley
- Robert B. DiasioRDRobert B. Diasio
- 1 January 2008
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 18 (1) , 25-35
Abstract
Approximately 30-40% of grade III-IV toxicity to 5-FU has been associated with partial or profound deficiency in dihydropyrimidine dehydrogenase (DPD), the first of three enzymes in the catabolic pathway of fluoropyrimidines. There remains, however, a subset of patients presenting with 5-FU-associated toxicity despite normal DPD activity, suggesting possible deficiencies in enzymes downstream of DPD: dihydropyrimidinase (DHP), encoded by the DPYS gene, and/or beta-ureidopropionase (BUP-1), encoded by the UPB1 gene. Previously, we reported the identification of inactivating mutations in the DPYS gene that could potentially alter the uracil catabolic pathway in healthy individuals with normal DPD enzyme activity. This study investigates the possible role of UPB1 genetic variations in the regulation of the uracil catabolic pathway in individuals presenting with a deficient uracil breath test (13C-UraBT) despite normal DPD enzyme activity. This study included 219 healthy asymptomatic volunteers with known DPD enzyme activity and [2-(13)C]-uracil breath test (UraBT). All samples were genotyped for sequence variations in the UPB1 gene using denaturing high performance liquid chromatography (DHPLC) and Surveyor enzyme digestion with confirmation of detected sequence variants by direct sequencing. Seven novel and six previously reported sequence variations were identified, including one nonconservative mutation, which demonstrated 97.3% reduction in BUP-1 activity when expressed in the RKO cell line. Data presented in this study demonstrate that alterations of uracil catabolism are not limited to DPD and/or DHP deficiency and that inactivating mutations in the UPB1 gene might impair uracil catabolism.Keywords
This publication has 29 references indexed in Scilit:
- Comprehensive Detection of Disorders of Purine and Pyrimidine Metabolism by HPLC with Electrospray Ionization Tandem Mass SpectrometryClinical Chemistry, 2006
- Activity of Pyrimidine Degradation Enzymes in Normal TissuesNucleosides, Nucleotides & Nucleic Acids, 2006
- β-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalitiesHuman Molecular Genetics, 2004
- Screening and diagnosis of β‐ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urineJournal of Mass Spectrometry, 2002
- Detection of β‐ureidopropionase deficiency with HPLC–electrospray tandem mass spectrometry and confirmation of the defect at the enzyme levelJournal of Inherited Metabolic Disease, 2001
- β‐Ureidopropionase deficiency: A novel inborn error of metabolism discovered using NMR spectroscopy on urineMagnetic Resonance in Medicine, 2001
- Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracilAdvances in Enzyme Regulation, 2001
- Expression and Properties of Human Liver .BETA.-Ureidopropionase.Journal of Nutritional Science and Vitaminology, 2001
- Dihydropyrimidinase Deficiency: Structural Organization, Chromosomal Localization, and Mutation Analysis of the Human Dihydropyrimidinase GeneThe American Journal of Human Genetics, 1998
- Population and family studies of dihydropyrimidinuria: Prevalence, inheritance mode, and risk of fluorouracil toxicityAmerican Journal of Medical Genetics, 1998